EGFR and non-small cell lung carcinoma: Recently, interim results from the ORIENT-31 phase III trial (NCT03802240) indicated that PFS was significantly longer (6.9 months vs. 4.3 months) in the sintilimab plus IBI305 (bevacizumab biosimilar) plus cisplatin and pemetrexed group (SBCP regimen) than in the chemotherapy alone group in EGFR-mutated NSCLC patients who progressed on previous EGFR-TKIs therapy [195].